DESTINY-Lung02
DESTINY-Lung02: Phase II Trial of Trastuzumab Deruxtecan in Patients With Previously Treated HER2-Mutated Metastatic NSCLC

Released: September 14, 2023

Activity

Progress
1
Course Completed